Neutrophil to lymphocyte ratio to define efficacy of the treatment with Ipilimumab or BRAF inhibitors (vemurafenib or dabrafenib) in patients with unresectable Stage III or IV melanoma

Trial Profile

Neutrophil to lymphocyte ratio to define efficacy of the treatment with Ipilimumab or BRAF inhibitors (vemurafenib or dabrafenib) in patients with unresectable Stage III or IV melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 26 Jul 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top